Veritable’s Neurocrine Biosciences NBIX Stock Holding History

Veritable’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,206	Closed	-$263K	–	905
2022 Q4	$263K	Buy	+2,206	New	+$258K	﹤0.01%	695

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Veritable's NBIX Position: Q1 2023 in Review

Veritable sold out of Neurocrine Biosciences (NBIX) in Q1 2023, closing a stake of 2,206 shares — an estimated $263K sold.

Veritable first reported a position in NBIX in Q4 2022 and held it in 1 quarter. The position peaked at $263K in Q4 2022. 486 funds tracked by Wall St. Rank hold NBIX as of Q1 2023.

Veritable reported no remaining Neurocrine Biosciences position as of Q1 2023 after selling out during the quarter.
Veritable sold 2,206 Neurocrine Biosciences shares in Q1 2023, an estimated $263K.
Veritable first reported a position in Neurocrine Biosciences in Q4 2022 and held it in 1 quarter.
Veritable's Neurocrine Biosciences position peaked at $263K in Q4 2022.
486 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2023.

Based on Veritable's 13F filing for Q1 2023, filed 12 May 2023.